According to our new research study on "Hospital at Home Market Forecast to 2031 -Global Analysis - by Component, Service Type, Delivery Mode, Patient Demographic, Indication, Care Provider, and Geography," the market is anticipated to grow from US$ 37.17 billion in 2025 to US$ 72.84 billion by 2034, with a CAGR of 7.8% during 2026-2034.

The hospital at home market growth is attributed to the rapidly aging population and rising prevalence of chronic diseases, constraints on hospital capacity, a shift toward ambulatory and community-based care, and advancements in digital health technologies.

The Hospital at Home (HaH) model provides hospital-level care to patients in their home settings. Different teams provide treatments such as IV therapies, monitoring, nursing visits, and diagnostics at home, usually helped by remote technologies. HaH models expose patients to fewer risks of hospital-acquired infections, while delivering treatment outcomes comparable to those of traditional hospital care. Some of the major market trends include device-based remote monitoring, sustainable and green healthcare, and integration of AI in HaH models.

The hospital at home market in North America is segmented into the US, Canada, and Mexico. The North America hospital at home market growth is supported by regulatory frameworks and demonstrated clinical benefits along with increasing adoption of acute inpatient-level care in patients' homes. The US holds the largest market share, followed by Canada.

The expansion of the hospital-at-home (HaH) model in the United States has been made possible by the Centers for Medicare and Medicaid Services (CMS) Acute Hospital Care at Home initiative. This program was created in November 2020 due to the COVID-19 public health emergency, providing acute level inpatient care to Medicare beneficiaries in their homes. By the middle of 2025, 400 hospitals across 140+ health systems had been approved to offer HaH services. Recent legislative activity includes the passage of H.R. 4313 by the House in December 2025, and various appropriations bills that extend funding for waivers of certain facility requirements through the year 2030 while ensuring that hospitals continue to meet safety standards. Examples include the Mount Sinai Health System's program to deliver support for treatment of heart failure and infections via remote monitoring and in-person visits to prevent complications (e.g., delirium and falls), and collaborative efforts between the Mayo Clinic and post-acute care providers to facilitate smoother transitions from acute care at home to continued post-acute care; and numerous rural and urban hospitals are using this model to free up inpatient beds. As part of its ongoing program evaluation, a 2024 CMS study will document lower mortality rates among HAAC (Acute Hospital Care) patients versus HAAC patients receiving services through traditional inpatient care. In addition to demonstrating lower mortality rates for HAAC patients than those receiving traditional inpatient services, the data from this study also substantiates the high levels of satisfaction experienced by HAAC patients, fewer readmissions among HAAC patients and greater mobility of HAAC patients. Collectively, these findings corroborate the effectiveness of HAAC in managing acute conditions, while aligning with patients' preference to recover from acute conditions in their homes, coupled with the availability of 24/7 dedicated clinical staff and access to multidisciplinary care teams.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the hospital at home market report.